Cancer drug fund extension relieves firms
This article was originally published in Scrip
England's Cancer Drugs Fund is set to live on for another two years beyond the date it was supposed to be superseded by a new pricing set up. Manufacturers of oncology drugs will likely welcome another two years of greater stability while uncertainty over the UK's pricing landscape continues.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.